

Release date: 5 May 2021

STONEHAVEN INCUBATE LAUNCHES NEW COMPANY AIMING TO TACKLE CANINE OSTEOARTHRITIS

Stonehaven Incubate has partnered with human health player Regenosine to launch Vetosine, a new company that will develop and commercialize a first-in-class disease modifying osteoarthritis drug (DMOAD) for animals, with an initial focus on dogs.

“Vetosine’s proprietary adenosine-based treatment will be a real game changer for the industry,” said Charlie Dawson, Venture Partner at Stonehaven Incubate. “At the moment, veterinarians and pet owners have few therapy options for dogs with osteoarthritis beyond simple nonsteroidal anti-inflammatory drugs (NSAIDs), diet and exercise. Vetosine will provide a proven disease modifying drug that will strengthen clinical outcomes and improve the pet’s quality of life.”

Dr. Bruce Cronstein, co-founder of Regenosine, was first to elucidate the role of adenosine in maintaining healthy joint cartilage.

“We have now developed proprietary formulations for adenosine replacement which have demonstrated disease modifying outcomes in gold standard preclinical models for osteoarthritis,” said Dr. Siddhesh Angle, co-founder and CEO of Regenosine. “While we endeavour to make this first-in-class therapy a success for human medicine, we are very excited to partner with Stonehaven Incubate to expand its horizon into the animal health space.”

Vetosine will have an exclusive global license to develop the new technology in animal health while Regenosine will continue to focus on developing the same technology for the human health market.

“Vetosine is perfectly aligned with Stonehaven Incubate’s mission to transform animal health by leveraging disruptive human health technologies,” said Jarne Elleholm, CEO of Stonehaven Incubate. “We are excited to add another company to our portfolio as we continue to explore other opportunities to translate breakthrough human health technologies into the animal health space.”

ends

Notes to editor:

Stonehaven Incubate

Swiss based Stonehaven Incubate was formed in February 2018 and is a dedicated, animal health group committed to creating new companies de novo from disruptive human technology. Stonehaven Incubate works with innovators and builds strategies for new, stand-alone animal health companies. It finds experienced management teams and sources the required capital, leaving no stone unturned in its quest to bring human innovations to animal health.

Regenosine

Regenosine is developing and commercializing first-in-class musculoskeletal regenerative therapies. Its proprietary platform technology harnesses the healing potential of the purinergic system which plays a critical role in maintaining musculoskeletal tissue homeostasis. The lead product is a proprietary formulation for regenerating cartilage in joints with established osteoarthritis, targeting a rapidly growing joint preservation market. The goal is to offer a disease modifying therapy with uncompromising efficacy relative to existing technologies. By developing this disease modifying therapy, Regenosine will significantly improve clinical outcomes and patient quality of life, and reduce the total health care delivery costs associated with osteoarthritis.

Vetosine

Vetosine is a new company focused on developing and commercializing disease modifying osteoarthritis drugs for dogs. It was founded by Stonehaven Incubate and Regenosine in 2021.

For more information contact Alistair Moses or Mike Keeler at Garnett Keeler PR on +44 (0)20 8647 4467 alistair.moses@garnettkeeler.com or mike.keeler@garnettkeeler.com

STO/024/21